NASDAQ:NRSN NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis $0.68 0.00 (0.00%) Closing price 07/17/2026 03:59 PM EasternExtended Trading$0.71 +0.03 (+3.95%) As of 07/17/2026 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About NeuroSense Therapeutics Stock (NASDAQ:NRSN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NRSN alerts:Sign Up Key Stats Today's Range$0.68▼$0.7350-Day Range$0.68▼$0.9052-Week Range$0.63▼$2.10Volume55,333 shsAverage Volume164,697 shsMarket Capitalization$22.27 millionP/E RatioN/ADividend YieldN/APrice Target$8.50Consensus RatingModerate Buy Company Overview NeuroSense Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system. At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration. By combining high-throughput screening with advanced medicinal chemistry and in vivo disease models, the company is advancing multiple small-molecule preclinical candidates toward Investigational New Drug (IND)-enabling studies. Key areas of focus include Alzheimer’s disease, Parkinson’s disease and other brain disorders linked to aging and cellular dysfunction. Founded by a team of neuroscientists and drug-discovery experts, NeuroSense is headquartered in Tel Aviv, Israel, with research operations extending to the United States. The company has established collaborations with leading academic institutions and contract research organizations to support its pipeline development. NeuroSense’s executive leadership brings extensive experience in biotechnology and pharmaceutical development, positioning the firm to translate its innovative science into potential new treatments for patients worldwide.AI Generated. May Contain Errors. Read More NeuroSense Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreNRSN MarketRank™: NeuroSense Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 408th out of 842 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingNeuroSense Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 1 strong buy rating, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNeuroSense Therapeutics has a consensus price target of $8.50, representing about 1,142.7% upside from its current price of $0.68.Amount of Analyst CoverageNeuroSense Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about NeuroSense Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for NeuroSense Therapeutics are expected to decrease in the coming year, from ($0.39) to ($0.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuroSense Therapeutics is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuroSense Therapeutics is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about NeuroSense Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.48% of the float of NeuroSense Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeuroSense Therapeutics has a short interest ratio ("days to cover") of 2.03, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroSense Therapeutics has recently increased by 18.99%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuroSense Therapeutics does not currently pay a dividend.Dividend GrowthNeuroSense Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest14 people have searched for NRSN on MarketBeat in the last 30 days. This is an increase of 1,300% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added NeuroSense Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership4.3 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of NeuroSense Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $400,000.00 in company stock, which represents 1.7961% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, NeuroSense Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $400,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders27.40% of the stock of NeuroSense Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions1.04% of the stock of NeuroSense Therapeutics is held by institutions.Read more about NeuroSense Therapeutics' insider trading history. Receive NRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NRSN Stock News HeadlinesNeurosense Therapeutics Ltd. (NRSN) Gets a Buy from Noble FinancialJuly 10, 2026 | theglobeandmail.comNeuroSense Therapeutics Ltd. Ordinary Shares (NRSN)July 8, 2026 | nasdaq.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"July 6, 2026 | prnewswire.comNeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALSJune 29, 2026 | prnewswire.comNeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's DiseaseJune 25, 2026 | prnewswire.comEverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the DotsJune 22, 2026 | prnewswire.comNeuroSense Granted South Korean Patent Covering PrimeC Composition for ALSJune 11, 2026 | prnewswire.comSee More Headlines NRSN Stock Analysis - Frequently Asked Questions How have NRSN shares performed this year? NeuroSense Therapeutics' stock was trading at $0.7690 at the start of the year. Since then, NRSN stock has decreased by 11.1% and is now trading at $0.6840. How were NeuroSense Therapeutics' earnings last quarter? NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) released its quarterly earnings data on Monday, April, 7th. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.06. When did NeuroSense Therapeutics IPO? NeuroSense Therapeutics (NRSN) raised $13 million in an initial public offering on Wednesday, December 8th 2021. The company issued 2,000,000 shares at $6.00-$7.00 per share. How do I buy shares of NeuroSense Therapeutics? Shares of NRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NeuroSense Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroSense Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Abbott Laboratories (ABT) and Energy Select Sector SPDR Fund (XLE). Company Calendar Last Earnings4/07/2025Today7/19/2026Next Earnings (Estimated)9/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 NRSN's financial health is in the Red zone, according to TradeSmith. NRSN has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NRSN CIK1875091 Webwww.neurosense-tx.com Phone972-9799-6183FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Price Target for NeuroSense Therapeutics$8.50 High Price Target$14.00 Low Price Target$3.00 Potential Upside/Downside+1,142.7%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.31 Quick Ratio0.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-13.68Miscellaneous Outstanding Shares32,560,000Free Float23,636,000Market Cap$22.27 million OptionableNot Optionable Beta1.58 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:NRSN) was last updated on 7/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredMy next big call (under $1)17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredThis same-day trade is getting a lot of attentionZero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...Base Camp Trading | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredPrint this and keep it by your screenEver been right about a stock's direction and still lost money on the trade? It's almost never bad luck - it's...Profits Run | SponsoredWhere to Put $100 Before Trump's New Tech Law Rolls OutThe Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NRSN Stock Alerts